Med·Invest | News: Medical Device Investment Highlights (May 25 – June 7, 2024)

Huichuang Medical Technology Co., Ltd. (hereinafter referred to as "Huichuang Medical") is a high-tech enterprise focusing on the medical device field, with its headquarters located in Jiangsu Province, China. The company is committed to the research and development, production, and sales of medical devices, with a product line covering multiple medical fields such as diagnostic equipment, therapeutic instruments, and monitoring systems. Through continuous technological innovation and product upgrades, Huichuang Medical has established itself in the market.

Established a good brand image and gained widespread recognition from medical institutions and professionals.

The business scope of Huichuang Medical not only includes traditional medical devices but also extends to emerging fields such as intelligent healthcare and telemedicine. The company actively expands collaborations with medical institutions, providing customized solutions to meet the needs of various medical scenarios. The products of Huichuang Medical, known for their efficiency, accuracy, and ease of use, help medical institutions improve service quality and operational efficiency.

Huichuang Medical has an experienced R&D team that continuously explores the frontier fields of medical technology, committed to developing more innovative medical devices to improve the accuracy of diagnosis and the success rate of treatment. The company also emphasizes the protection of intellectual property rights, owning multiple patented technologies, which ensures the technical leadership and market competitiveness of its products.

This tens of millions of RMB B+ round of financing will bring new development opportunities for Huichuang Medical. The company plans to use this fund to increase R&D investment, optimize service systems, expand product lines, and enhance market competitiveness. Huichuang Medical looks forward to accelerating technological innovation and market expansion through cooperation with Shengjing Jia Cheng and Xingfu Capital, thereby improving the company's core competitiveness.

Xunjie Guangyuan Technology Co., Ltd. (hereinafter referred to as "Xunjie Guangyuan") recently announced that it has successfully completed an A+ round of financing worth hundreds of millions of RMB. This round of financing was jointly invested by Genesis Capital, Xianting Fund, and Fortune Venture Capital, with the funding amount ranking in the top 20% of all A+ rounds in the current year. Headquartered in Jiangsu Province, China, Xunjie Guangyuan is a high-tech enterprise specializing in the manufacturing of near-infrared spectrometers.

Since its establishment, Xunjie Guangyuan has been committed to the research and application of near-infrared spectroscopy technology. Its products are widely used in various fields such as chemical industry, pharmaceuticals, agriculture, and food. The company's main products include portable near-infrared spectrometers, online near-infrared monitoring systems, and laboratory near-infrared analyzers. These products, with their high precision, high stability, and ease of operation, help customers achieve rapid, non-destructive material analysis and quality control.

Xunjie Guangyuan's product line not only covers traditional near-infrared spectroscopy analysis instruments but also actively expands into emerging technology fields such as smart sensors, big data, and cloud computing. Through continuous technological innovation and product upgrades, the company provides comprehensive solutions to meet the needs of different industries and application scenarios.

The company has a research and development team composed of industry experts and senior engineers, who have rich experience and deep technical accumulation in the field of near-infrared spectroscopy technology. Xunjie Guangyuan focuses on intellectual property protection and owns several core patented technologies, ensuring the technological leadership and market competitiveness of its products.

The success of this A+ round of financing will further accelerate XunJie Guangyuan's development in the near-infrared spectroscopy technology field.

Xinyong Technology Co., Ltd. (hereinafter referred to as "Xinyong Technology") recently announced that it has successfully completed a multi-million RMB Series A round of financing. This round of financing was jointly invested by Frees Fund and Xingfu Capital. Headquartered in Beijing, China, Xinyong Technology is an innovative medical device provider specializing in blood pressure monitoring technology.

Xinyong Technology focuses on the development of high-precision blood pressure monitoring devices, with a product line covering smart blood pressure monitors, wireless blood pressure monitoring systems, and an integrated data analysis platform. These innovative products utilize the latest medical technologies and intelligent algorithms to provide users with accurate and convenient blood pressure monitoring services, while supporting healthcare professionals in effective patient monitoring and management.

Xinyong Technology's intelligent blood pressure monitoring solution is not only suitable for personal home health monitoring but also widely used in professional medical institutions such as hospitals and community healthcare centers, helping to improve the quality and efficiency of medical services. The company provides comprehensive technical support for the prevention, monitoring, and management of hypertension through its advanced technology platform.

The company has a research and development team composed of experts from the fields of healthcare, bioengineering, and information technology. They possess profound expertise and practical experience in the fields of telemedicine and intelligent medical devices. Xinyong Technology is committed to meeting the needs of the market and patients through continuous technological innovation, driving the development of health technology.

The completion of Series A financing will inject new momentum into Xinyong Technology. The company will use this funding to further accelerate the product development process, expand market channels, and deepen cooperation with the healthcare industry. Xinyong Technology looks forward to working hand-in-hand with Frees Fund and Xingfu Capital to jointly promote the company's continuous growth in the smart medical device field and establish its industry leadership.

Xiangya Biomedical (Huzhou) Co., Ltd. (hereinafter referred to as "Xiangya Bio") recently announced that the company has completed a multi-million RMB Series A round of financing. This round of investment was jointly led by Jinfu Capital and Haisheng Fund. Xiangya Bio, a medical device developer located in Zhejiang Province, China, focuses on providing innovative medical aesthetics products and services.

Xiangya Bio is a company that integrates research and development, production, sales, and service, committed to incorporating the concept of "self-healing, self-generation, and nature" into its product line. The company's main products include recombinant humanized collagen protein liquid dressings, which have significant applications in the medical aesthetics field, aiming to provide safer and more effective treatment solutions. Xiangya Bio’s product development is based on full-length recombinant collagen protein and function-enhanced recombinant collagen protein technology, striving to become a game-changer in the field of collagen repair.

The company's co-branding customization service provides personalized solutions for partners, meeting the specific demands of the market for customized medical products. Xiangya Bio actively participates in industry events, such as assisting in organizing lectures on legal practices for medical aesthetics institutions, demonstrating its commitment and support for the healthy development of the industry.

The success of this Series A round of financing marks a solid step for Xiangya Bio in the capital market. The company plans to use the raised funds to strengthen its R&D capabilities, expand production scale, enhance product market competitiveness, and explore new opportunities in domestic and international markets. Through cooperation with Jinfu Capital and Haisheng Fund, Xiangya Bio will gain more resources and support to accelerate its innovation and development in the medical aesthetics industry.

Hengdao Pathology Technology Co., Ltd. (hereinafter referred to as "Hengdao Pathology") recently announced that it has successfully completed a multi-million RMB B+ round of financing. This round of financing was jointly invested by Changxing Financial Control and PuHua Capital. Hengdao Pathology, as a tumor diagnosis and treatment service provider located in Shanghai, China, focuses on providing innovative intelligent pathology solutions.

Hengdao Pathology provides patients with convenient application for HPV testing, early screening for colorectal cancer, and electronic report inquiry services through its online service platform. The company is also actively building a pathology academic and educational community, offering pathologists a space for in-depth exchange and growth through Hengdao Medical New Media.

Technological innovation is one of Hengdao Pathology's core competencies. The company's launched WisPath® Full-process Intelligent Digital Pathology Quality Control System has been applied in multiple medical institutions, significantly improving the efficiency and accuracy of pathological diagnosis. In addition, the cooperation between Hengdao Pathology and Roche Diagnostics has further promoted the construction of a digital pathology ecosystem, injecting new momentum into the development of precision medicine.

The successful completion of the B+ round of financing marks that Hengdao Pathology has gained full recognition and support in the capital market. The injection of funds will help the company increase its R&D efforts, expand its service scope, improve service quality, and seek broader development opportunities in the global market. The cooperation with Changxing Financial Control and Puhua Capital will bring new growth opportunities to Hengdao Pathology, promoting the company to achieve leapfrog development in the field of intelligent pathology services.

The honors and qualifications obtained by Hengdao Pathology in 2024 fully demonstrate its leading position and professional capabilities among non-public medical institutions. Shanghai Hengdao Medical Pathology Diagnosis Center has been awarded the AAA-level unit for social credit evaluation and the five-star unit for medical quality service capability evaluation. These honors are not only a recognition of Hengdao Pathology's past achievements but also an encouragement for its future development.